0.059
0.00 (0.00%)
| Previous Close | 0.059 |
| Volume | 2,352,152 |
| Price / Sales | 806.76 |
| Price / Book | 5.04 |
| 52 Weeks Range |
| Profit Margin | -181.62% |
| Operating Margin (TTM) | -49.62% |
| Diluted EPS (TTM) | -0.010 |
| Quarterly Revenue Growth (YOY) | 77.00% |
| Current Ratio (MRQ) | 11.24 |
| Operating Cash Flow (TTM) | -6.09 M |
| Levered Free Cash Flow (TTM) | -4.60 M |
| Return on Assets (TTM) | -45.61% |
| Return on Equity (TTM) | -85.35% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (AU) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | AROVELLA FPO [ALA] | - | - |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 3.5 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | 0.0 |
| Average | 2.33 |
|
Arovella Therapeutics Ltd is engaged in the development of its invariant Natural Killer T (iNKT) cell platform for the treatment of cancer. Its invariant Natural Killer T (iNKT) cell therapy platform is being developed as a next-generation, allogeneic off-the-shelf cell therapy platform with potential applications across blood cancers, solid tumours and selected autoimmune diseases. Its product, ALA-101, is a CD19-directed CAR-iNKT cell therapy for relapsed or refractory CD19- positive blood cancers. Arovella is expanding the platform into solid tumours through ALA-105, its CLDN18.2-targeting CAR-iNKT program for gastric and pancreatic cancers, and through incorporation of IL-12-TM armouring technology designed to enhance CARiNKT cell activity and durability. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 27.32% |
| % Held by Institutions | 5.29% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |